Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC)
Herbst R, Sun Y, Korfee S, Germonpré P, Saijo N, Zhou C, Wang J, Langmuir P, Kennedy S, Johnson B. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC). Journal Of Clinical Oncology 2009, 27: cra8003-cra8003. DOI: 10.1200/jco.2009.27.18_suppl.cra8003.Peer-Reviewed Original ResearchNon-small cell lung cancerProgression-free survivalObjective response ratePhase III trialsAddition of vandetanibVandetanib armIII trialsOverall survivalStage IIIB/IV non-small cell lung cancerAdvanced non-small cell lung cancerDouble-blind phase III trialPrevious first-line chemotherapyRandomized phase II studyDaily oral inhibitorSecond-line treatmentAdverse event profileDeterioration of symptomsFirst-line chemotherapyPhase II studyCell lung cancerCommon AEsPFS prolongationII studySecondary endpointsBaseline characteristics